Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 19/20 | 0.80 |
| ▸ | KLK1 | P06870 | 4/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15142762 | 0.99 | KLKB1 (0.79) | KLKB1KLK1HDAC1HDAC6 | |
| SCHEMBL1981938 | 0.89 | KLKB1 (1.00) | KLKB1KLK1 | |
| Hydrochloric Acid SCHEMBL1985633 | 0.88 | KLKB1 (0.98) | KLKB1KLK1 | |
| SCHEMBL30739101 | 0.87 | KLKB1 (0.83) | KLKB1KLK1 | |
| Acetic Acid SCHEMBL29253774 | 0.86 | KLKB1 (0.94) | KLKB1KLK1 | |
| SCHEMBL30739095 | 0.86 | KLKB1 (0.82) | KLKB1KLK1 | |
| SCHEMBL30739034 | 0.85 | KLKB1 (0.84) | KLKB1KLK1 | |
| SCHEMBL30739063 | 0.83 | KLKB1 (0.77) | KLKB1KLK1 | |
| SCHEMBL30739146 | 0.83 | KLKB1 (0.77) | KLKB1KLK1 | |
| SCHEMBL16365832 | 0.82 | KLKB1 (0.79) | KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378474-A1 | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | NOVARTIS AG (CH) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378474-A1 | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885KLK1 3/4885HDAC1 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.